Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04612751 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 1 study of Advanced or Metastatic NSCLC, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT04612751 is a Phase 1 study of Advanced or Metastatic NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 155 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT04612751, a Phase 1 study of Advanced or Metastatic NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Durvalumab
- DRUG Datopotamab deruxtecan
- DRUG AZD2936
- DRUG MEDI5752
Study Locations (20)
Other
- Research Site - Hasselt
- Research Site - Roeselare
- Research Site - Aviano
- Research Site - Meldola
- Research Site - Orbassano
- Research Site - Roma
- Research Site - Kōtoku
- Research Site - Sunto-gun
- Research Site - Yokohama
- Research Site - Gdansk
Texas
- Research Site - Dallas
- Research Site - Houston
- Research Site - San Antonio
California
- Research Site - La Jolla
- Research Site - Santa Ana
Missouri
- Research Site - St Louis
New Jersey
- Research Site - Hackensack
Ohio
- Research Site - Cleveland
Pennsylvania
- Research Site - Philadelphia
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2021-02-02 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04612751
The ClinicalTrials.gov registry entry for NCT04612751 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04612751 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT04612751 about?
NCT04612751 is a clinical study titled "Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer". This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
What is the current status of trial NCT04612751?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2021-02-02. Estimated completion is 2026-04-30.
What conditions does trial NCT04612751 study?
This clinical trial studies the following conditions: Advanced or Metastatic NSCLC.
What interventions are being tested in trial NCT04612751?
The interventions under investigation include: Carboplatin (DRUG), Durvalumab (DRUG), Datopotamab deruxtecan (DRUG), AZD2936 (DRUG), MEDI5752 (DRUG).
Who is sponsoring clinical trial NCT04612751?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04612751 being conducted?
This trial has 20 study locations across California, Missouri, New Jersey, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.